Dr. Casey Wang, M.D
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 356
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license Q1050 (first issued 2014; active) -
Internal Medicine Physician
TX license BP10046714
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Bellaire Dermatology Associates PA (11 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 356
- Services billed
- 1,559
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 732 | 142 |
| Established patient office or other outpatient visit, 30-39 minutes | 254 | 212 |
| Destruction of precancer skin growth, 1 growth | 218 | 199 |
| Established patient office or other outpatient visit, 20-29 minutes | 195 | 165 |
| Biopsy of related skin growth, first growth | 134 | 132 |
| New patient office or other outpatient visit, 45-59 minutes | 98 | 98 |
| New patient office or other outpatient visit, 30-44 minutes | 86 | 86 |
| Established patient office or other outpatient visit, 10-19 minutes | 49 | 41 |
| Destruction of skin growth, 1-14 growths | 47 | 43 |
| Punch biopsy, first skin growth | 38 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 118 payments worth $2,610 in total to this clinician.
| Pfizer Inc. | $458 |
|---|---|
| Arcutis Biotherapeutics, Inc. | $404 |
| AbbVie Inc. | $312 |
| Janssen Biotech, Inc. | $266 |
| Genzyme Corporation | $249 |
| Sun Pharmaceutical Industries Inc. | $163 |
| Journey Medical Corporation | $124 |
| Regeneron Healthcare Solutions, Inc. | $120 |
| Food and Beverage | $2,543 |
|---|---|
| Education | $66.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Oct 13, 2025 | Education TREMFYA · Immunology · in-kind | $66.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,030 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.